Fact Check: BPC-157, TB-500, and Epitalin are on the verge of gaining FDA approval for compounding in the U.S.

Claim: BPC-157, TB-500, and Epitalin are on the verge of gaining FDA approval for compounding in the U.S.

Verdict: Partially True (80% confidence)

Explanation: According to the FDA's official website, an advisory panel recommended BPC-157, TB-500, and Epitalin for inclusion on the 503A Bulks List, which is a step towards FDA approval for compounding (FDA.gov). However, the FDA has not yet made a final decision, and there are concerns about safety and efficacy, as noted by other sources (Texas Orthobiologics, RiteAid). These sources highlight that while the advisory panel's recommendation is a significant step, it does not equate to full FDA approval, w...